Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses (Tables)

v3.8.0.1
Acquisitions, Investments, and Licenses (Tables)
12 Months Ended
Dec. 31, 2017
Business Acquisition [Line Items]  
Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments
The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of December 31, 2017:
(in thousands)
 
 
 
 
Investment type
 
Investment Carrying Value
 
Underlying Equity in Net Assets
Equity method investments
 
$
23,338

 
$
18,210

Variable interest entity, equity method
 
402

 

Available for sale investments
 
12,461

 
 
Cost method investment
 
1,108

 
 
Warrants and options
 
3,333

 
 
Total carrying value of investments
 
$
40,642

 
 
Transition Therapeutics, Inc.  
Business Acquisition [Line Items]  
Schedule of Purchase Price Allocation
The following table summarizes the final purchase price allocation and the fair value of the net assets acquired and liabilities assumed at the date of acquisition:
(In thousands)
 
Transition Therapeutics
Current assets
 


Cash and cash equivalents
 
$
15,878

IPR&D assets
 
41,000

Goodwill
 
3,453

Other assets
 
634

Accounts payable and other liabilities
 
(1,035
)
Deferred tax liability
 
(1,400
)
Total purchase price
 
$
58,530